Morgan Stanley started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a report released on Tuesday morning, Marketbeat reports. The brokerage issued an overweight rating and a $25.00 price target on the stock.
Separately, Stifel Nicolaus initiated coverage on shares of Contineum Therapeutics in a research note on Tuesday. They set a buy rating and a $29.00 price target for the company.
View Our Latest Report on Contineum Therapeutics
Contineum Therapeutics Stock Performance
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
See Also
- Five stocks we like better than Contineum Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- 3 Best Fintech Stocks for a Portfolio Boost
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- What is a Secondary Public Offering? What Investors Need to Know
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
